As a company at the forefront of the psychedelic renaissance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has differentiated itself by focusing on what most psychedelic drug development companies are not. Guided by an exceptional roster of scientific advisors and an experienced management team led by Tryp chairman and CEO Greg McKee, Tryp is developing psychedelic compounds targeting diseases with high unmet medical needs through its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program.
The PFN program, which features TRP-8802 as the lead drug candidate and TRP-8803 as the proprietary formulation with a novel method of administration, targets chronic pain conditions, including fibromyalgia, phantom limb pain, complex regional pain syndrome and others, as well as eating disorders such as hypothalamic obesity, binge eating disorder and others.
Tryp intends to proceed directly into Phase 2a human trials by leveraging existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803. To this end, it has partnered with leading academic institutions that have indication-specific expertise needed for the trials. Tryp has also entered into an agreement with a contract development and manufacturing organization (“CDMO”) for the research, development and GMP manufacturing services for synthetic psilocybin that will form the basis of the PFN program. It has further engaged another CDMO to develop the analytical methods and final formulations of its TRP-8802 and TRP-8803 products (https://ibn.fm/FUSJx).
According to a recent press release, the company will present at the conference, with Greg McKee providing an overview of the business and its pipeline updates, including the PFN program. Tryp’s presentation will be available on-demand starting at 7:00 a.m. EDT on Sept. 13 (https://ibn.fm/F5YQU).
Founded in 2019 and headquartered in San Diego, California, Tryp Therapeutics has made significant progress that positions it favorably in the promising psychedelic medical market. It is also similarly poised to leverage growth opportunities spanning multiple therapeutics markets, in line with its commitment to lead the next wave of psychedelic drug development beyond mental health.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
A team of researchers has leveraged a technique called temporal learning to train an AI…
Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year…
“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…
Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…
A new study focusing on twins has found that individuals with a larger presence of…